©enterlinedesign / Shutterstock.com
The outlook for diabetes drug treatment over the next few years is promising for type 2 and type 1 patients. Well known pharmaceutical companies, such as Johnson & Johnson, Novo Nordisk, Abbott Laboratories, Sanofi-Aventis, Merck, Bayer, and Roche are leaders in the diabetes drug and device arena but new companies are involved as well. Market competition will increase with companies setting up operations in emerging markets. China and India, two of the biggest markets are expected to account for much of the growth of the treatment market. This trend will stimulate innovation and price reduction which will provide access to treatments for poorer patients.
A little further down the pipeline is a device/system called The Bionic Pancreas which uses both insulin and glucagon along with a continuous glucose monitor that are controlled by a smartphone. This is truly a game changer and when it comes to market the diabetes world will take notice.
To view market insights, please register. If you have already registered, please enter your information below.